skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: In your Mar 23 response, you indicated guidance was key...so I scanned their 2015 AR looking for guidance. I expected to find some 2016 goals and a CEO signature. Only found the Executive Summary...where the only guidance is they "expect" to de-lever by paying down some debt...& unsigned. No commitment or targets there. Your thoughts?
Read Answer Asked by BRIAN on March 28, 2016
Q: Can you please shed some light on why CXR is down 8% since the call this morning? I thought the call was positive and it helped to break the correlation to Valeant's business issues. What on the call is being interpreted so negatively by the markets? This doesn't impact my decision to hold long term as I got in at a very high price, just trying to educate myself on market moves. Thanks again and again...John C.
Read Answer Asked by john on March 24, 2016
Q: Hey

Just a question on Phm. I'm holding for the next quarter results to see how things are going but does it not seem to be trading awfully strange. As if it's being held down at these what I perceive to be very low levels? There's been some crazy talk of a potential sale do you think that's a reason it's remainly at such low levels? Finally if you don't mind what do you think of Concordia now. I took first position at 35 last week on drop.
Read Answer Asked by jason on March 24, 2016
Q: I noticed in your question/answer dated Mar 16/16, you talk about the quarter report, but I'm sure you sent me an email saying Mar 21/16 when the quarter report was coming out & CXR on the 23. Question: Could you give me the results for both companies.
Read Answer Asked by Earl on March 24, 2016
Q: Peter et al.

What do you make of their earnings results released today? Did they beat estimates? They showed a loss in earnings due to acquisition charges. Was this expected? EBIDTA was good from what I see ($120M). Revenue was good as well as far as I can see. Is this still a long term hold?

Regards,


Brendan
Read Answer Asked by Brendan on March 23, 2016
Q: Please comment on their latest quarter.
Include debt/adjusted ebitda ratio.
Read Answer Asked by sandy on March 23, 2016
Q: I hold JPM and INVN in my US portfolio. INVN has not done much and JPM seems to be too dependent on the Fed.
What is your opinion on these two stocks and would I be better off selling these two and buying GILD.
(also own BRK.B, CVS, INTC, IWO, QQQ, VIG in my US account)

Thanks
Read Answer Asked by Irshad on March 23, 2016
Q: Dear Team,
how would you rate these two biotech stocks? Trillium, having received financing, is now considered a 'strong buy'.
Thank you for your input!
Read Answer Asked by Sigrid on March 22, 2016
Q: Would like your view on pli after today's news,
sounds promising. Expensive here?
Thanks
Read Answer Asked by howard on March 22, 2016
Q: AMGN seems to have a broader range of products on the market than GILD which appears to be hepatitis-c drug weighted, so why is AMGN not the better stock to purchase in your view? Thanks for your take vis-a-vis these two US stocks.
Read Answer Asked by Doug on March 22, 2016
Q: would you buy gild or uhn both of them or neither one?
Read Answer Asked by Gary on March 22, 2016
Q: would you buy it at todays prices?
what safety level would you rank it at
Read Answer Asked by Gary on March 21, 2016
Q: Any comments on today's news item about a relationship with a company and product I have never heard of? Market seems to have liked it somewhat on much above average volumn.
Read Answer Asked by george on March 21, 2016
Q: Hello.
As most, I am not accustom to having my capital cut by 25% in 4 days like I have experienced with CXR. My bad for being drawn into this type of investment.
As I am here now, I was expecting to see someone ask for your market experienced comment on what we just witnessed this week and how to deal with it.....as I wonder what is next.
Is there a story that goes with this cut in share price? (Wise and Seasoned Investors getting out before earnings?) Or do we just sit blindly believing it is all due to Valiant?
Appreciate your input.
Thanks

Read Answer Asked by David on March 21, 2016
Q: Hi Peter, How do you analyze the current situation? I heard on CNBC that it is not in debt holder's interest to serve them default notice as then debt will go down more in short term. What else is unknown? If we all agree with the guidance it is 2.5X 2016 earnings now. Do they have to issue any new debt? If not then there is no question of their borrowing rate going up. Am I right? So how does this temporary situation have any real business implications? You can figure out from my tone that I am long on this name. Now here is my reason for being long. 1. Every day 10000 people in north america turning 60 until 2030, so they got tailwind for derma and GI. 2. Also they have diversified across eastern Europe and mexico, so again well diversified. 3. US congress and senate still held by republicans, so even Hillary/Sanders cannot pass anything to curb drug prices in 2017-2018. 4.They have 3 very successful activist(2 valueAct, 1 pershing) on their board, who will extract value, also I hope they did/still doing extensive due diligence. 5. Debt- it is not mining or oil, they will have strong cash flow around $2 billion to pay the debt. Anyways, can you please come up with some points that a guy with short position will think at this price point?? Also please correct me if I am wrong in my long assumptions. I would better be wrong than loose money.
Read Answer Asked by Sridip on March 18, 2016
Q: What is the consensus in US dollars for Q4's revenue, adjusted ebitda and adjusted eps?

thx

Read Answer Asked by sandy on March 18, 2016
Q: peter i made a few bucks lat year and bought in at 0.60 is there a hope or should i bail thanks
Read Answer Asked by aldo on March 17, 2016
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!